Compare IMKTA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | NUVB |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | IMKTA | NUVB |
|---|---|---|
| Price | $88.99 | $4.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 104.4K | ★ 3.1M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.09 | $1.57 |
| 52 Week High | $95.62 | $9.75 |
| Indicator | IMKTA | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 36.00 |
| Support Level | $86.93 | $4.06 |
| Resistance Level | $89.76 | $5.42 |
| Average True Range (ATR) | 2.30 | 0.27 |
| MACD | -0.40 | -0.03 |
| Stochastic Oscillator | 24.21 | 6.67 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.